Buhmann, C. Impaired mitochondrial calcium uptake caused by tacrolimus underlies beta-cell failure. Yubero, D.

Coenzyme Q mitochondrial function -

Effects of CoQ 10 during Tac-induced mitochondrial ROS production in INS-1 cells. The mitochondrial bioenergetics of whole cells was determined by calculating oxygen consumption over time after the sequential addition of inhibitors of mitochondrial function.

Effect of CoQ 10 on mitochondrial function during Tac-induced injury in INS-1 cells. a The areas under the curve for basal respiration, b ATP production, maximal respiration, proton leak, and non-mitochondrial respiration were calculated from the OCR.

The current study was performed to investigate whether cotreatment with CoQ 10 is effective in ameliorating pancreatic beta cell dysfunction by Tac. The results of our study showed that CoQ 10 attenuated hyperglycemia and restored the insulin secretion ability by reducing Tac-induced oxidative stress.

These findings suggest that CoQ 10 produces beneficial effects for reducing mitochondrial injury via its antioxidative properties during Tac-induced beta cell injury Fig. The results of our study thus provide a rationale for use of CoQ 10 as supplemental therapy in Tac-induced DM in clinical practice.

Proposed mechanism of the protective effect of CoQ 10 during Tac-induced pancreatic beta cell injury. In this study, we first evaluated whether the administration of CoQ 10 was effective in controlling hyperglycemia in an experimental Tac-induced DM model. Recently, several clinical studies have shown that CoQ 10 treatment reduces DM 34 , 35 , In this study, we found that the AUCg based on IPGTT was increased and the plasma insulin level and insulin-immunoreactivity in islets were decreased by chronic Tac treatment.

However, cotreatment with CoQ 10 significantly decreased the AUCg and increased levels of plasma insulin and GSIS compared with the levels observed following Tac treatment alone. Furthermore, immunostaining of insulin in islets revealed that concomitant treatment with CoQ 10 resulted in increases in islet size and immunoreactivity for insulin, as well as preservation of islet morphology as demonstrated by less irregular islet boundaries and reduced vacuolization.

These findings suggest that CoQ 10 has beneficial effects on the preservation of beta cells during Tac treatment. To elucidate the possible mechanism of CoQ 10 in the control of hyperglycemia, we evaluated the expression of markers of oxidative stress in the experimental groups, as oxidative stress has been suggested to be an important pathway in the pathogenesis of pancreatic beta cell injury.

High levels of oxidative stress induced by Tac administration lead to islet cell death and dysfunction, with short- and long-term Tac treatment inducing the production of ROS, thereby causing apoptotic cell death 32 , Therefore, it has been proposed that a reduction in oxidative stress could protect from pancreatic beta cell injury.

Based on this hypothesis, we focused on the antioxidative effect of CoQ 10 on Tac-induced oxidative injury in pancreatic beta cells. For this, we measured the expression of 8-OHdG and 4-HHE, markers of oxidative DNA and lipid damage, respectively, and found that while their expression levels were increased in beta cells in Tac-treated mice, administration of CoQ 10 attenuated these increases in expression levels.

Indeed, there is evidence to show that the development of diabetes is associated with increased oxidative stress and that CoQ 10 can scavenge ROS, resulting in an anti-hyperglycemic effect Overall, our data indicate that oral administration of CoQ 10 is effective in reducing Tac-induced oxidative stress in pancreatic beta cells.

We further evaluated whether the antioxidative effect of CoQ 10 ameliorated mitochondrial injury during Tac treatment. The mitochondria play important roles in pancreatic beta cells from glucose metabolism to insulin exocytosis, thereby ensuring tight regulation of glucose-stimulated insulin secretion Impairment in the mitochondrial function affects this metabolic coupling and ultimately leads to apoptosis and beta cell death.

Furthermore, mitochondria are susceptible to oxidative damage and could be a major source of superoxide under disease conditions Based on this knowledge, we first examined rates of apoptosis, a mitochondrial pathway of cell death in vivo and in vitro , and found that CoQ 10 reduced the numbers of TUNEL- and annexin V-positive cells compared with those in the Tac group.

Ultrastructural analysis revealed that Tac treatment caused reductions in the number, area, size, and volume of mitochondria, as well as the number of insulin granules, while CoQ 10 administration attenuated these changes.

CoQ 10 also reduced accumulation of mitochondrial ROS and superoxide anion and restored basal respiration, ATP-linked respiration, and maximal respiration rates according to oxygen consumption over time. These data suggest that administration of CoQ 10 helps to maintain mitochondrial function during Tac-induced oxidative stress, resulting in a subsequent decrease in apoptotic cell death.

In addition to Tac, rapamycin analogs, sirolimus SRL and everolimus EVR , have been widely used as immunosuppressants in transplantation, but they are also associated with an increased risk of DM.

Many studies have demonstrated that both of these drugs cause mitochondrial dysfunction in pancreatic beta cells, eventually leading to decreased insulin release 40 , 41 , 42 , We have also confirmed that SRL or EVR treatment alone results in the development of hyperglycemia, accompanied by a reduction in the number of insulin granules and an increase in the expression of oxidative stress markers, in animal models 27 , 30 , However, addition of CoQ 10 attenuated SRL-induced hyperglycemia, as well as oxidative stress, in a rat model.

At the subcellular level, CoQ 10 also improved not only the morphology of the mitochondria but also mitochondrial respiration Based on these findings, CoQ 10 supplementation would also be beneficial in the treatment of rapamycin-induced DM. In conclusion, CoQ 10 plays an important role in reducing Tac-induced oxidative stress and protecting mitochondria in pancreatic beta cells.

These findings suggest that CoQ 10 may be useful in the management of Tac-induced DM in the future. Kasiske, B. Diabetes mellitus after kidney transplantation in the United States.

Am J Transplant 3 , — Article Google Scholar. Weir, M. Impact of immunosuppressive regimes on posttransplant diabetes mellitus. Transplant Proc 33 , 23s—26s Article CAS Google Scholar.

Heit, J. et al. Nature , — Article ADS CAS Google Scholar. Soleimanpour, S. Calcineurin signaling regulates human islet {beta}-cell survival. J Biol Chem , — Demozay, D. Diabetes 60 , — Yang, J. PANDER binds to the liver cell membrane and inhibits insulin signaling in HepG2 cells.

FEBS Lett , — Donelan, M. Implications for regulated beta-granule transport and insulin exocytosis. Lawrence, M. Mol Endocrinol 15 , — Redmon, J.

Effects of tacrolimus FK on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest 98 , — Harbeck, M. Expression of insulin receptor mRNA and insulin receptor substrate 1 in pancreatic islet beta-cells.

Diabetes 45 , — Ishizuka, J. Effects of FK and cyclosporine on dynamic insulin secretion from isolated dog pancreatic islets. Transplantation 56 , — Piao, S. Combined treatment of tacrolimus and everolimus increases oxidative stress by pharmacological interactions.

Transplantation 98 , 22—28 Trinanes, J. Deciphering Tacrolimus-Induced Toxicity in Pancreatic beta Cells. Am J Transplant 17 , — Lenaz, G. The role of Coenzyme Q in mitochondrial electron transport. Mitochondrion 7 Suppl , S8—33 Crane, F. Biochemical functions of coenzyme Q J Am Coll Nutr 20 , — Bentinger, M.

The antioxidant role of coenzyme Q. Mitochondrion 7 Suppl , S41—50 Huo, J. Coenzyme Q10 Prevents Senescence and Dysfunction Caused by Oxidative Stress in Vascular Endothelial Cells. Oxid Med Cell Longev , Venegoni, W. The use of antioxidants in the treatment of traumatic brain injury.

J Adv Nurs 73 , — Ishikawa, A. Beneficial effect of ubiquinol, the reduced form of coenzyme Q10, on cyclosporine nephrotoxicity.

Int Braz J Urol 38 , —; discussion Chen, H. Free Radic Res 22 , — Upaganlawar, A. Modification of biochemical parameters of gentamicin nephrotoxicity by coenzyme Q10 and green tea in rats. Indian J Exp Biol 44 , — CAS PubMed Google Scholar.

Sohet, F. Coenzyme Q10 supplementation lowers hepatic oxidative stress and inflammation associated with diet-induced obesity in mice. Biochem Pharmacol 78 , — Spindler, M. Coenzyme Q10 effects in neurodegenerative disease. Neuropsychiatr Dis Treat 5 , — CAS PubMed PubMed Central Google Scholar.

Lombardi, A. Impaired mitochondrial calcium uptake caused by tacrolimus underlies beta-cell failure. Cell Commun Signal 15 , 47 Sun, I. The effects of addition of coenzyme Q10 to metformin on sirolimus-induced diabetes mellitus.

Korean J Intern Med Jin, J. Effect of Empagliflozin on Tacrolimus-Induced Pancreas Islet Dysfunction and Renal Injury. Drug interaction between cyclosporine and mTOR inhibitors in experimental model of chronic cyclosporine nephrotoxicity and pancreatic islet dysfunction.

Transplantation 93 , — ER, W. Stereologkal methods vol 1. Academic Press Inc. Bonner-Weir, S. Beta-cell turnover: its assessment and implications. Diabetes 50 Suppl 1 , S20—24 Effects of metformin on hyperglycemia in an experimental model of tacrolimus- and sirolimus-induced diabetic rats.

Korean J Intern Med 32 , — Jin, L. Effects of addition of a dipeptidyl peptidase IV inhibitor to metformin on sirolimus-induced diabetes mellitus. Transl Res , — Lim, S. Ginseng extract reduces tacrolimus-induced oxidative stress by modulating autophagy in pancreatic beta cells.

Lab Invest 97 , — Dott, W. Modulation of mitochondrial bioenergetics in a skeletal muscle cell line model of mitochondrial toxicity. Redox Biol 2 , — Yen, C. Effect of liquid ubiquinol supplementation on glucose, lipids and antioxidant capacity in type 2 diabetes patients: a double-blind, randomised, placebo-controlled trial.

Br J Nutr , 57—63 Gholami, M. Effects of coenzyme Q10 supplementation on serum values of adiponectin, leptin, 8-isoprostane and malondialdehyde in women with type 2 diabetes. Gynecol Endocrinol , 1—5 Stojanovic, M.

A meta-analysis of randomized and placebo-controlled clinical trials suggests that coenzyme Q10 at low dose improves glucose and HbA1c levels.

Nutr Res 38 , 1—12 Effect of Exendin-4 on Autophagy Clearance in Beta Cell of Rats with Tacrolimus-induced Diabetes Mellitus. Sci Rep 6 , Supale, S. Mitochondrial dysfunction in pancreatic beta cells.

Trends Endocrinol Metab 23 , — Smith, R. Mitochondria-targeted antioxidants in the treatment of disease. Ann N Y Acad Sci , — Suzuki, L. Everolimus Directly Suppresses Insulin Secretion Independently of Cell Growth Inhibition.

J Endocr Soc 2 , — Manzia, T. Ab initio Everolimus-based Versus Standard Calcineurin Inhibitor Immunosuppression Regimen in Liver Transplant Recipients. Transplant Proc 50 , — Sirolimus induces depletion of intracellular calcium stores and mitochondrial dysfunction in pancreatic beta cells.

Sci Rep 7 , Article ADS Google Scholar. Constantinescu, A. Differential influence of tacrolimus and sirolimus on mitochondrial-dependent signaling for apoptosis in pancreatic cells. Mol Cell Biochem , 91— Download references.

Convergent Research Consortium for Immunologic Disease, Seoul St. Transplant Research Center, The Catholic University of Korea School of Medicine, Seoul, Republic of Korea.

Department of Internal Medicine, Seoul St. Advanced Analysis Center, Korea Institute of Science and Technology, Seoul, Korea. Integrative Research Support Center, The Catholic University of Korea School of Medicine, Seoul, Republic of Korea.

You can also search for this author in PubMed Google Scholar. and C. designed the research and wrote the report; K.

and Y. conducted the animal experiments; K. and H. conducted the electron microscopic analysis; S. and E. performed the cell culture studies; K. analyzed the data and edited the manuscript. Correspondence to Sun Woo Lim.

Open Access This article is licensed under a Creative Commons Attribution 4. Reprints and permissions. Luo, K. Therapeutic potential of coenzyme Q 10 in mitochondrial dysfunction during tacrolimus-induced beta cell injury. Sci Rep 9 , Download citation.

Received : 12 September Accepted : 17 May Published : 29 May Anyone you share the following link with will be able to read this content:. Sorry, a shareable link is not currently available for this article. Provided by the Springer Nature SharedIt content-sharing initiative.

European Journal of Applied Physiology By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily. Skip to main content Thank you for visiting nature. nature scientific reports articles article.

Download PDF. Subjects Kidney Metabolic disorders. Abstract We previously reported that oxidative stress induced by long-term tacrolimus treatment impairs mitochondrial function in pancreatic beta cells.

Introduction Tacrolimus Tac , a calcineurin inhibitor CNI , is the most commonly used immunosuppressant. Materials and Methods Ethics statement All procedures were performed in strict accordance with the recommendations of the ethical guidelines for animal studies.

Experimental rat model Male Sprague-Dawley SD rats Orient Bio, Seongnamsi, Korea were provided a 0. Basic treatment protocol Animals were pair-feeding and their body weight was monitored.

Pancreatic function and beta cell area in islets After the 4-week treatment, an intraperitoneal glucose tolerance test IPGTT was conducted for measurement of the glucose level. Immunohistochemistry After processing with the retrieval solution pH 6. Measurement of beta cell mass The relative volumes of beta cells were estimated by the point-counting method Measurement of 8-OHdG in serum The end product of oxidative DNA damage was measured by determining the concentration of 8-OHdG in serum.

Some of them function as enzymes and others as structural components of the CoQ biosynthetic complex Fig. Mutations in COQ genes cause primary CoQ 10 deficiency PCoQD , a clinically heterogenous and rare disorder [ 12 , 13 ].

Symptoms often resemble those of typical inborn mitochondrial respiratory chain disorders Fig. It some cases the symptoms predominantly affect a particular organ or tissue e. Secondary CoQ 10 deficiency refers to all the conditions in which the etiology of a CoQ 10 deficiency is not a molecular lesion in the CoQ 10 biosynthetic pathway [ 17 , 18 ].

In fact, a variety of conditions have been found to be associated with CoQ 10 deficiency. Statins were shown to reduce serum and muscle CoQ 10 levels [ 19 , 20 ].

Mutations in the electron transfer flavoprotein dehydrogenase ETFDH , and mitochondrial DNA mtDNA lesions, including low mtDNA copy number, were also shown to lower steady state level of CoQ 10 [ 21 - 26 ].

The mechanisms leading to deficiency in these cases are unknown, except for the effect of statins, which inhibit the synthesis of mevalonate, the molecular precursors of the CoQ 10 sidechain. A The final steps of CoQ 10 biosynthesis are carried out in the inner mitochondrial membrane.

The CoQ 10 biosynthetic pathway includes both enzymes in blue and structural or regulatory components in purple. Only the numbers in their names are shown for COQ proteins COQ, COQ8A, COQ8B and COQ9. They are known to form a large complex, the CoQ biosynthetic complex or CoQ-synthome. COQ10A and COQ10B whose functions are uncertain and not known to be part of the complex are not shown.

The most essential function of CoQ 10 is to transport electrons in the mitochondrial respiratory chain. Although CoQ 10 is found in the mitochondrial membrane, in the figure this is not shown for clarity. B Primary CoQ 10 deficiency predominantly manifests as mitochondrial disorder, with organs with high energy needs being most often affected.

C Intestinal absorption of CoQ 10 is thought to occur through the formation of mixed micelles with other dietary lipids. Once inside the enterocytes, CoQ 10 is incorporated into chylomicrons CM which are transported via the lymphatics to the blood circulation. Because of its extreme hydrophobicity and its relatively large size, the absorption of orally administered CoQ 10 has been reported to be poor.

In tissue samples or cultured cells from patients, CoQ 10 deficiency can be diagnosed by measuring CoQ 10 levels, which can be complemented by the observation of impaired CoQ 10 -dependent respiratory chain activities Complex I-III and Complex II-III.

In the last few decades, with the increasing availability and affordability of genomic sequencing technology, whole genome or exome sequencing is increasingly becoming the first-line diagnostic test for patients suspected of having genetic disorders, including PCoQD.

This has accelerated the discovery of novel PCoQD disease variants [ 27 ]. Disease-causing mutations have been reported for 9 out of 11 COQ genes required for CoQ biosynthesis. Below we report that at least PCoQD patients have been reported so far.

CoQ 10 supplementation is frequently initiated immediately after diagnosis Fig. However, there is lack of clear evidence for such a claim.

In fact, it is a component of the so-called mitochondrial cocktail which is a collection of high-dose nutraceuticals with the potential to support mitochondrial functioning [ 36 ]. Moreover, CoQ 10 is recommended for treating a wide range of other conditions e.

By estimation, the global market size of CoQ 10 amounts to close to M USD a year. This review aims to summarize and evaluate the available evidence for the effectiveness of CoQ 10 supplementation for the treatment of PCoQD. Patients with PCoQD should be the most amenable to CoQ 10 treatment because their CoQ 10 deficiency is the only cause of all their symptoms and therefore CoQ 10 treatment is simple replacement therapy.

Thus, examining outcomes of CoQ 10 treatment for these patients is the first key step to address the effectiveness of any CoQ 10 therapy and to promote a rational use of CoQ 10 for disease treatment or as a health supplement.

A literature search was performed in PubMed for studies that described PCoQD patients, up until May 01, The PubMed query used is given in Supporting Information. The references cited in the articles identified were manually screened for any additional relevant study.

We imposed no publication status or language restrictions. We considered any type of study regardless of research design. The following information was sought in each paper: descriptive characteristics of PCoQD patients including sex, age of onset, major symptoms, age at the last reported exam or death, molecular lesions in COQ genes or proteins, severity of CoQ 10 deficit, respiratory chain complex RCC activities, CoQ 10 treatment received and clinical outcomes, and laboratory tests known to be relevant to mitochondrial disease.

CoQ 10 levels and RCC activities are most often reported in patient-derived skin fibroblasts or muscle biopsies. Study data were extracted by one reviewer YW and verified by another reviewer SH for accuracy, narrative summaries, and interpretation.

When data were reported more than once for the same patients, which was exceedingly rare, the data that were included were those from the most recent comprehensive report. If no data on patient treatment with CoQ 10 was provided in a study, or if patients were treated but outcome data was not reported, or the reported effects were contradictory or ambiguous, the study was excluded from the final data synthesis Fig.

We synthesized data using tabulations that include narrative summaries. Fulfilling any one of the first two criteria is defined as responding with an objective description of the response.

Whereas if symptom improvement was described without relying on any quantifiable measure, we categorize it as a subjective description of the response to CoQ 10 therapy. No restriction on CoQ 10 dosage dose, formulation, dose frequency , time of initial treatment, duration of treatment, or concurrent treatments was made.

The two authors independently assigned the patient cases to the categories. Disagreements were resolved by discussion and consensus. The literature search yielded 78 published studies, from which a total of patients with PCoQD were identified.

Their characteristics are summarized in Table 1 , and details are available in Table S1. Of the PCoQD patients, [ Following the exclusion criteria, 53 treated patients were removed from the final analysis Table S2.

Among the excluded patients, 16 were excluded because the reported follow-up findings were judged to be ambiguous or inadequate to judge treatment efficiency, for example reports that mention symptom stabilization or CoQ 10 treatment combined with other simultaneous treatments.

All other exclusions were because no treatment outcome was reported. In the final analysis, we included and assessed a total of 89 patients. The results are shown in Table 2.

Details, including total count of patients treated and numbers of exclusions for each gene, can be found in Table S3. We classified 65 out of the 89 patients Among those, there are nine cases in which patients showed infantile onset and multisystem involvement.

Such cases may be more challenging to treat, but this is only speculation. Of the 24 cases Note, however, that all responses were partial, and responses are frequently only observed with a single symptom.

Four out of the five also reported recovery to some extent following treatment resumption. These cases potentially provide the most tantalizing evidence for a partial efficacy of CoQ 10 treatment for CoQ deficiency.

We should note, however, that the possibility of placebo effects cannot be excluded. Of the other 15 cases of responses with objective description, four cases reported a decrease of proteinuria after CoQ 10 treatment as an indication of kidney function improvement and ten reported a reduction in a severity score of ataxia or another motor performance test at a follow-up.

However, five of the patients classified as responders because of an amelioration of proteinuria had only kidney symptoms, and in two cases only proteinuria. Treatment effects established by quantitative or semi-quantitative measures to describe the response to CoQ 10 treatment were counted as responding with objective description, while descriptions of positive effects but without relying on a quantitative or semi-quantitative measures were counted as responding with subjective description.

As shown in Fig. No substantial adverse effects have been reported for the CoQ 10 -treated PCoQD patients. However, an adverse reaction has been reported in one case of treatment with the synthetic CoQ analogue idebenone which has a hydroxydecyl instead of a decaprenyl side chain and higher solubility than CoQ 10 [ 45 ].

Two graphs are shown for dosage comparison because CoQ 10 treatment dosages were reported in 2 different units. In humans, mutations have so far been reported in all the genes required for CoQ 10 biosynthesis, except COQ3.

COQ3 is an O-methyltransferase and it is the only COQ protein that is required for more than one step in the CoQ biosynthetic pathway [ 46 ]. Thus, one possible explanation for the lack of reports of COQ3 patients is that, because it is required for two enzymatic steps, pathogenic mutations in COQ3 are more detrimental to CoQ production and thus are more likely to be lethal.

Among the reported PCoQD patients, The reason for the higher COQ8A and COQ8B patient counts is most likely because genetic screening studies were performed for COQ8A and COQ8B on a relative larger scale.

Two studies reported screening for COQ8A mutations in patients with ataxic symptoms, resulting in the identification of 69 patients carrying rare biallelic variants [ 15 , 39 ].

Screens for COQ8B mutations in patients with renal disorders, including nephrotic syndrome and chronic renal failure, were described in three studies, which in total reported the identification of 63 COQ8B patients [ 47 - 49 ].

COQ8A and COQ8B are orthologs of yeast Coq8p, which plays a regulatory role in CoQ biosynthesis [ 40 , 47 , 50 ]. COQ8A is expressed in most tissues, but there is a relative enrichment of COQ8B in podocytes [ 47 , 51 ].

Consistently, COQ8B patients were described to have a less severe clinical course and manifest largely kidney-limited phenotypes [ 47 , 52 ]. Thus, the mutation frequency observed for a given COQ gene is likely influenced by the role it plays in CoQ biosynthesis and its tissue expression pattern.

Often CoQ 10 deficiency patients are started on oral CoQ 10 supplementation immediately after diagnosis. Various oral formulations of CoQ 10 are available [ 61 ]. The scientific literature as well as the general media mostly state that oral CoQ 10 supplementation is effective and thus that CoQ 10 deficiency is treatable [ 33 ].

However, to the best of our knowledge, there is no other evidence that could support such a belief than the set of studies reviewed here. The final step of our analysis is based on published studies on 89 PCoQD patients for which we consider there to be sufficient information available to estimate the clinical effectiveness of the CoQ 10 treatment.

Of them, 65 cases fit our criteria for not-responding, including patients with age of onset ranging from neonatal to 42 years of age and that present with multi-system symptoms or primarily one organ-specific manifestation e. Among the 24 cases identified as responsive, 12 cases reported improvement of an ataxia rating score and 7 out of them are patients with COQ8A mutations for whom ataxia is often the most prominent symptom.

Five cases reported proteinuria improvement at a post-treatment follow-up, and in all five of them renal dysfunction was the only manifestation.

However, many PCoQD patients with ataxia or kidney symptoms were reported to show no response or the condition continued to deteriorate after CoQ 10 treatment Table S4. Therefore, the observed relative prevalence of positive effects on ataxia or proteinuria does not indicate that the kidneys and cerebellum are more sensitive to supplemental treatment with CoQ Furthermore, in patients with multisystem manifestations, effects were reported only for a few symptoms and most of the other symptoms still persisted after CoQ 10 treatment.

Detrimental effects of treatment interruption were noted in five cases, which potentially constitute the best evidence for some effectiveness of CoQ 10 therapy. However, as these are not blinded studies, the possibility of placebo effects remains of concern.

Overall, most descriptions of the effects of CoQ 10 treatment have incomplete information and lack a complete clinical picture. Doctors and patients are aware of the treatments i. For these reasons, we consider the cases where a minimal effect only was reported as not responding to treatment.

It has been hypothesized that CoQ treatment cannot reverse severe tissue damage due to PCoQD when the disease has already progressed too far before therapy is initiated [ 30 , 62 ]. However, animal studies with an unnatural CoQ biosynthetic precursor suggest that most phenotypes due to severe CoQ deficiency can be completely rescued by a partial replenishment of CoQ levels [ 63 - 65 ].

Therefore, it is reasonable to expect that significant clinical benefits should be possible even in severely impaired PCoQD patients if in fact a significant amount of CoQ 10 were absorbed and could reach affected tissues.

The results from our analysis indicate that most PCoQD patients treated with CoQ 10 showed little or no response, and, in the cases of positive reports, the overall clinical benefit was only very limited. This strongly suggests a lack of efficacy of CoQ 10 treatment. It is noteworthy that clinical trials have been conducted to assess the potential benefit of CoQ 10 in the treatment of patients with secondary CoQ 10 deficiency or mitochondrial disease.

CoQ 10 supplementation was shown to elicit no benefit to the patients with statin-induced myalgia [ 66 ]. To date, only few double-blind and randomized clinical trials evaluating CoQ 10 in the treatment of mitochondrial disorders have been completed. There were reports of minor effects for improved muscle strength and attenuation of lactate rise post-exercise.

However, the overall conclusion remained that CoQ 10 is ineffective for the treatment of patients with mitochondrial disorder, or at least there is no solid evidence to suggest otherwise [ 67 , 68 ]. CoQ 10 is extremely lipophilic and practically insoluble in water; therefore, to develop pharmaceutical CoQ preparations, a number of formulation strategies for insoluble compounds have been tried, such as oil solution, emulsion, cyclodextrin complexation, and liposomal nanoencapsulation [ 69 ] Presently, all currently marketed formulations of CoQ 10 are for oral administration only.

Like all dietary lipids, orally administered CoQ 10 is absorbed in the enterocytes, packaged into chylomicrons large lipoprotein particles and then transported via the lymphatics to the circulation Fig.

Increases several-fold above normal plasma level has been reported after CoQ 10 treatment [ 70 - 72 ]. However, it is not known how blood CoQ 10 concentration is related to effectiveness in relieving symptoms. Moreover, the mechanism of tissue uptake of CoQ 10 is still poorly understood.

In rodents, after oral CoQ 10 supplementation high concentrations of CoQ 10 were reported for several tissues including the liver, ovaries, brown adipocytes, and spleen after feeding CoQ 10 -supplemented food or water, but not for the heart, kidney, muscle and brain, the main affected tissues in PCoQD [ 63 , 73 - 77 ].

Key factors that influence the tissue or cellular uptake of CoQ 10 await future studies. There have been discussions on the possible merits of using the reduced form of CoQ 10 , also known as ubiquinol, to enhance the bioavailability of CoQ 10 [ 78 ]. Out of the 89 cases included in our final analysis, 6 were reported to be treated with ubiquinol Table S4 and S5.

Two met our criteria of responding and 4 did not. Thus, this data also does not point to better bioavailability of ubiquinol over regular CoQ 10 in PCoQD patients. In sum, the results of the present review suggest the need to develop alternative strategies of providing CoQ 10 and stresses the need for caution when seeking to justify the widespread use of CoQ 10 for disease treatment or as a dietary supplement.

Our recent study suggests the possibility of intravenously administering CoQ 10 solubilized with the fungicide caspofungin to achieve much higher plasma concentration and thus more effective CoQ 10 therapy [ 79 ]. Furthermore, modified precursors of the quinone ring of CoQ 10 , for example, DHB, have been considered as potential alternative treatment option for some types of PCoQD [, 80, 81].

Future work is warranted to further explore these possibilities and unleash the full potential of CoQ 10 therapy. SH and YW designed the study. YW did literature searches and extracted data. SH verified data accuracy, narrative summaries, and interpretations.

Both authors contributed to the selection of included studies, evaluation of data quality, and data analyses.

SH and YW wrote the manuscript together and approved the final manuscript. Research in the laboratory of SH is funded by a Foundation grant from the Canadian Institutes of Health Research: FDN SH is Campbell Chair of Developmental Biology. SH and YW have received royalty payment from Clarus Therapeutics Holdings.

SH also consults for Clarus Therapeutics Holdings. Table S1: Primary CoQ 10 deficiency patients identified by literature search. Table S3: Partial effects reported for CoQ 10 treatment of primary CoQ deficiency patients.

Table S5: Cases with positive outcomes following CoQ 10 treatment, classified as responding. View the discussion thread. Supplementary Material. Skip to main content. The efficacy of coenzyme Q 10 treatment in alleviating the symptoms of primary coenzyme Q 10 deficiency: a systematic review Ying Wang , Siegfried Hekimi.

Ying Wang. Abstract Coenzyme Q 10 CoQ 10 is necessary for mitochondrial electron transport. Studies of the effects of supplementation necessarily lacked controls and blinding.

All reported positive responses to treatment only partially improved few symptoms. CoQ 10 supplementation for the treatment of any disease should be questioned.

Introduction Coenzyme Q 10 CoQ 10 , also known as ubiquinone UQ 10 , is composed of a redox active aromatic ring and a ten-repeat long polyprenyl sidechain. Figure 1. CoQ 10 in the mitochondria, pathology of CoQ 10 deficiency and oral supplementation. MATERIALS AND METHODS Search strategy and selection criteria A literature search was performed in PubMed for studies that described PCoQD patients, up until May 01, Figure 2.

Flow diagram for identification and selection of primary CoQ 10 deficiency patients. Data analysis We synthesized data using tabulations that include narrative summaries.

RESULTS The literature search yielded 78 published studies, from which a total of patients with PCoQD were identified. View this table: View inline View popup Download powerpoint.

Table 1. Primary CoQ 10 deficiency patients reported in the literature. Table 2. Reported partial effects of CoQ 10 treatment in primary CoQ deficiency patients. Table 3. Therapeutic efficacy of CoQ 10 suggested by the effects of treatment interruptions.

Figure 3. The violin plots of CoQ 10 treatment dose and duration. Data Availability All data produced in the present work are contained in the manuscript.

FUNDING Research in the laboratory of SH is funded by a Foundation grant from the Canadian Institutes of Health Research: FDN Table S2: Cases excluded from the final analysis and reasons for their exclusion. Table S4: Patient cases classified as not responding to CoQ 10 treatment.

S1: The violin plot of total CoQ 10 amounts taken. REFERENCE 1. and S. Hekimi , Understanding Ubiquinone. Trends Cell Biol , OpenUrl CrossRef PubMed. Quinzii , C. Front Physiol , Lenaz , G.

and M. Genova , Structure and organization of mitochondrial respiratory complexes: a new understanding of an old subject. OpenUrl CrossRef PubMed Web of Science. Crane , F.

J Am Coll Nutr , Morre , D. and D. Morre , Non-mitochondrial coenzyme Q. Biofactors , Bentinger , M. Brismar , and G. Dallner , The antioxidant role of coenzyme Q. Mitochondrion , S41 — Tran , U. and C. Clarke , Endogenous synthesis of coenzyme Q in eukaryotes.

S62 — Wang , Y. Hekimi , Molecular genetics of ubiquinone biosynthesis in animals. Crit Rev Biochem Mol Biol , Stefely , J. Pagliarini , Biochemistry of Mitochondrial Coenzyme Q Biosynthesis. Trends Biochem Sci , Hekimi , The Complexity of Making Ubiquinone.

Trends Endocrinol Metab , Tsui , H. Clarke , Ubiquinone Biosynthetic Complexes in Prokaryotes and Eukaryotes. Cell Chem Biol , Ogasahara , S. Proc Natl Acad Sci U S A , Hughes , B.

Harrison , and S. Hekimi , Estimating the occurrence of primary ubiquinone deficiency by analysis of large-scale sequencing data. Sci Rep , Doimo , M. Mol Syndromol , OpenUrl PubMed.

Functlon Coenzyme Q mitochondrial function mitochonrdial visiting nature. You Coenzyme Q mitochondrial function using a browser Protein and weight management with limited support for CSS. To functlon the best experience, we recommend you Coenzym a more up to date browser or turn off compatibility mode in Internet Explorer. In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. We previously reported that oxidative stress induced by long-term tacrolimus treatment impairs mitochondrial function in pancreatic beta cells. Coenzyme Q CoQ is an Coenyzme Diabetic foot infections of the mitochondrial electron functino chain Coenzyyme an mitoochondrial in plasma membranes and lipoproteins. Mifochondrial is endogenously produced Functiion all cells by a highly regulated pathway that involves Nutrition for optimal performance mitochondrial multiprotein Mitocchondrial. Here, we review the current knowledge of CoQ 10 biosynthesis and mitochondial CoQ 10 deficiency Electrolytes and muscle performance, and have collected published results from clinical trials based on CoQ 10 supplementation. There is evidence that supplementation positively affects mitochondrial deficiency syndrome and the symptoms of aging based mainly on improvements in bioenergetics. Cardiovascular disease and inflammation are alleviated by the antioxidant effect of CoQ There is a need for further studies and clinical trials involving a greater number of participants undergoing longer treatments in order to assess the benefits of CoQ 10 treatment in metabolic syndrome and diabetes, neurodegenerative disorders, kidney diseases, and human fertility. Coenzyme Q CoQ, ubiquinone is a unique lipid-soluble antioxidant that is produced de novo in animals Laredj et al.

Video

How Your Body Creates Energy - CoQ10 Benefits - Mitochondrial Energy Support - Optimize Performance